Drug-eluting Stent: Where is the Way Out?
Yu Liu,Hua He,Dongsheng Zhao
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20130440
2013-01-01
Abstract:Since the first Palmaz-Schatz bare-metal stent (BMS) was implanted in human body in 1985, coronary stenting successfully resolved problem of the high restenosis rate in balloon dilatation era and soon became the primary means of clinical treatment of coronary artery disease. In order to meet the requirement of further reduction of the restenosis rate, drug-eluting stent (DES) was developed more than a decade later. With the excellent clinical efficacy, DESs established a milestone in the field of percutaneous coronary intervention (PCI). However, since the “stent thrombosis (ST) storm” triggered in 2006, the late ST after DES implantation quickly became a challenging problem.1,2 To solve this problem, a lot of advances have been achieved. Among them, biodegradable polymers and abluminal coating are two new technologies with bright future. DES WITH BIODEGRADABLE POLYMERS The causes of ST after implanting the first-generation DES are clearly multifactorial, and a portion of the blame has been attributed to the permanent polymer.3 Although the second-generation DES have already demonstrated impressive safety results at long-term follow-up,4,5 additional improvements are anticipated from the newer permanent polymer DES that have been developed. However, concerns persist over the presence of a nonerodable polymer, which remains exposed to the coronary artery environment long after its useful function has been served. Evidence from animal and human studies have suggested that these nonerodable polymers can cause persistent arterial wall inflammation and delayed vascular healing, both of which may subsequently have a role in precipitating ST and delayed restenosis.6-8 The findings from these studies accelerated the development of DES coated with biodegradable polymers. These stents offer the attractive combination of controlled drug elution in parallel with biodegradation of the polymer into inert monomers. Therefore, after biodegradation is complete, only a BMS remains, thereby reducing the long-term risks associated with the presence of a permanent polymer.9 In the issue of Chinese Medical Journal, a study from Kan et al10 demonstrates: (1) DES with either biodegradable or permanent polymer had lower value of late lumen loss (LLL); (2) LLL was less severe in the distal segment in relative to in-stent and proximal segment. In this non-randomized study, 300 consecutive patients having only biodegradable polymers or permanent polymer sirolimus eluting stent (SES) for all diseased vessels were enrolled (150 in EXCEL® biodegradable polymer group and 150 in FIREBIRD® permanent polymer group). The authors did not find the significant difference in LLL between the two groups. The study is timely necessary to elucidate the superiority of one domestic DES over another. And those results provided us a strong evidence to guide our clinical practice in the future. A randomized study is probably needed to identify the clinical benefit of one DES over the others other than angiographic parameters. In the issue of Chinese Medical Journal, Zhang et al11 conclude that: (1) Women had a lower major adverse cardiac events (MACE) and cardiac death rate than men after biodegradable polymer-coated SES (EXCEL®) in long term follow-up; (2) Effects of prolonged (over 6 months) dual antiplatelet therapy (DAPT) in preventing ST were similar with 6-month DAPT after EXCEL® stent implantation in both men and women groups, which has significant implication in patients who can not endure long term DAPT. Whether or not women gender is an independent predictor for worse outcome after PCI is still a subject of debate. Some studies confirm this phenomenon,12 whereas others have shown that the poorer outcomes in women are due to the presence of more clinical risk factors and comorbidities.13 More recent data suggest that long-term major clinical events14 and post-PCI mortality were not significantly different between men and women.15 In fact, in the BARI trial women was even a stronger predictor of better outcome than men after successful revascularization.16 So far, no prospective study has specifically focused on the evaluation of new generation DESs in women. The finding that EXCEL® stents for the treatment of women was superior is particularly encouraging. In present study, although women had higher proportions of clinical risk factors in comparison with men, the clinical results of cardiac death and MACE after index PCI procedures showed a low risk in women. The latter results suggested that a 6-month DAPT strategy after EXCEL® stent implantation might be safe for both men and women, which was consistent with the outcomes drawn from general patient cohorts.11,17-19 However, this conclusion needs further confirmation by head to head randomized trials. DES WITH ABLUMINAL COATING Abluminal coating can maximize the drug released into the vessel wall and minimize the systemic effect. Such a technique may facilitate a better stent endothelialization with positive impact on stent safety, minimizing long-term inflammation and decreasing ST rate, while maintaining anti-restenosis effect. Excel® stent is the first domestic device using abluminal coating design.19 Recently, its satisfactory and sustained five-year clinical safety and efficacy has been reported,17 evidenced by the low rates of MACE and ST when patients were treated with six months DAPT. Another domestic DES using abluminal design is FIREHAWK® stent. In addition to abluminal coating, its groove design allows the reduced drug content compared to previous generation DES. In this issue of Chinese Medical Journal, Xu et al20 showed: (1) The treatment of long coronary lesions with FIREHAWK® stent produces the similar results as observed in the FIREHAWK® FIM clinical trial;21 (2) The authors are optimistic of the treatment prospect of the FIREHAWK® for long coronary lesions. Those results are consistent with previous studies that LLL of FIREHAWK® is at the lower level compared with most other researches on DESs designed for treatment of long coronary artery diseases.22-24 One year results of FIREHAWK® TARGET I randomized controlled trial were released at TCT 2012, and its safety and efficacy have been approved. We are expecting long term (3-5 years) follow-up results from the serial studies. The articles previously introduced highlight the wealth of new DES technology and it is clear that no single DES design and polymer type will be suitable for all patients and lesion types. Therefore, a more individualized choice of DES, taking into account patient characteristics such as the ability to take long-term DAPT, and lesion characteristics such as presence or not of a bifurcation lesion will be important factors influencing DES selection. Encouragingly, the new DES technology appears to allow interventional cardiologists to make these choices, and there is great anticipation that the new DES technology will result in improved long-term clinical efficacy and safety.